Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Relapsed of refractory multiple myeloma Or relapsed or refractory B-Cell NHL
    After at least 2 prior regimens

HR 59

A Phase Ia/Ib open –label, multicenter study evaluating the safety and pharmacokinetics of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma

https://clinicaltrials.gov/ct2/show/NCT04045028

Criteria to qualify for this study: Drug used in study:
  • Ecog < 3; LVET > 50%

HR 64

A phase 1 open label, multicenter, dose escalation study of PRT1419 in subjects with relapsed/refractory hematological malignancies.

https://clinicaltrials.gov/ct2/show/NCT04543305

Criteria to qualify for this study: Drug used in study:
  • Relapsed CAR-T

MM 88 Poseida PBMCS – 101 – 001

Open-Label, Multi-Center, Single Ascending Dose Study to Assess the Safety of P-BMCA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT03288493

Criteria to qualify for this study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

https://clinicaltrials.gov/ct2/show/NCT03530683

Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory Multiple Myeloma or relapsed or refractory NHL; received at least 2 prior lines of therapy

HR 68

A phase I/II open-label, multi-center study to characterize the safety and tolerability of CFT7455 in subjects with relapsed/refractory Non-Hodgkin Lymphoma or Multiple Myeloma.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04756726

Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory MM after 3+ lines of therapy.

MM113

A Single-Arm, Open-Label, Phase 1 Study of the safety, efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-715 to evaluate and Anti-BCMA Allogeneic CAR-T Cell Therapy in subjects with relapsed/refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04093596

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed multiple myeloma with 4-8 cycles of induction and autologous stem cell transplant, archived bone marrow biopsy sample collected before induction or transplant.

MM 109

A randomized study of Daratumumab plus Lenalidomide vs. Lenalidomide alone as maintenance treatment in patients with newly diagnosed Multiple Myeloma who are minimal residual disease positive after frontline Autologous stem cell transplant.

https://clinicaltrials.gov/ct2/show/NCT03901963

Criteria to qualify for study: Drug used in study:
  • Received at least 2 cycles of initial therapy for MM

MM 117

A Multicenter, open-label, single arm Phase II study of Daratumumab as consolidation/maintenance therapy after Autologous Stem Cell Transplantation on patients with Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT03346135

Criteria to qualify for study: Drug used in study:
  • ISS Stage 3 Newly diagnosed MM; no more than 3 complete cycles of induction therapy

MM 120

A Phase 1, Open-Label, Multicenter study to evaluate the safety of BB2121 in subjects with High Risk, Newly Diagnosed Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04196491

Criteria to qualify for study: Drug used in study:
  • At least 3 prior lines of therapy (including proteasome inhibitor, immune modulatory drug, and an anti-CD38 antibody)

MM 121

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion study of the safety, tolerability, and Pharmocokinetics of HPN217 in patients with Relapsed/Refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04184050

Criteria to qualify for study: Drug used in study:
  • At least 3 prior lines including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 drug; ECOG of 0 or 1

MM 127

A phase 1, multicenter, open label study of CC-95266 in subjects with relapsed and or refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04674813

Criteria to qualify for this study: Drug used in study:
  • Symptomatic R/R MM or newly diagnosed MM; ECOG <3

MM 128

A Phase 1b/2 study of Selinexor (KPT-330) in combination with backbone treatments for relapsed/refractory and newly diagnosed Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT02343042

Criteria to qualify for study: Drug used in study:
  • 1 to 3 prior lines including a proteasome inhibitor and an immunomodulatory drug; refractory to Lenalidomide.

MM 129

A phase 3 randomized study comparing JNJ-68284528, a chimeric antigen receptor T Cell (CAR-T) Therapy directed against BCMA vs Carfilzomib and Dexamethasone (Kd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in participants with relapsed and Lenalidomide refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04181827

Criteria to qualify for study: Drug used in study:
  • PENDING – 3 or more prior lines of therapy; ECOG of 0 or 1

MM 131

A multi-arm phase 1b study of Teclistamab with other anticancer therapies in participants with Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04557098

Criteria to qualify for study: Drug used in study:
  • R/R MM after at least 3 prior lines; ECOG<2

MM 138

A single arm, open-label, phase 1/2 study evaluating the safety, efficacy and cellular kinetics/ pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Akkigenic CAR-T Cell Therapy in patients with relapsed/refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT05000450